Despite being preventable and curable, tuberculosis remains the world’s deadliest infectious disease. Around the globe, marginalized communities carry a disproportionate burden, with more than 80% of TB cases and deaths occurring in low- and middle-income countries. Growing drug resistance is compounding the public health challenge.
New medicines are needed to outpace drug resistance and end TB once and for all. We’re working in our own labs and with partners around the world to advance research and development (R&D) to find shorter, safer and simpler regimens needed to address the unmet needs of patients worldwide.